These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 30372907)

  • 1. Recent updates on GLP-1 agonists: Current advancements & challenges.
    Sharma D; Verma S; Vaidya S; Kalia K; Tiwari V
    Biomed Pharmacother; 2018 Dec; 108():952-962. PubMed ID: 30372907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
    Meier JJ
    Nat Rev Endocrinol; 2012 Dec; 8(12):728-42. PubMed ID: 22945360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.
    Mentlein R
    Expert Opin Investig Drugs; 2005 Jan; 14(1):57-64. PubMed ID: 15709922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albiglutide: Is a better hope against diabetes mellitus?
    Sharma AK; Thanikachalam PV; Rajput SK
    Biomed Pharmacother; 2016 Feb; 77():120-8. PubMed ID: 26796275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
    Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
    Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.